Tecentriq Approved for Unresectable or Metastatic Alveolar Soft Part Sarcoma
The approval was based on data from a phase 2 study that included 49 patients with unresectable or metastatic ASPS.
Diagnosis & Disease Information
Predicting the Risk of Thoracic Soft Tissue Sarcoma After Breast Cancer
There are several factors that may increase the risk of thoracic soft tissue sarcoma in patients with a history of breast cancer.
Eponyms in Oncology: Kaposi Sarcoma
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake for Kaposi sarcoma.
Fyarro Now Available for Malignant Perivascular Epithelioid Cell Tumor
Fyarro has also been added to the NCCN Guidelines as the only preferred treatment regimen for malignant PEComa.
Increased Risk of Neurocognitive Difficulties in Survivors of Bone Cancer
Researchers sought to measure the risk of long-term neurocognitive outcomes in survivors of osteosarcoma and Ewing sarcoma.
High Rate of Complications Reported in Sarcoma Patients With COVID-19
The hospitalization rate was 49%, and 16% of patients died.
Survey Reveals ‘Striking’ Barriers to Accessing High-Priority Cancer Drugs
Respondents said some essential cancer drugs had substantial out-of-pocket costs, and some posed a high risk of catastrophic expenditure.
Treatment Approaches Differ by Age Group in Extremity Soft Tissue Sarcoma
Young adults were more likely to receive chemotherapy.
Changes in Clinical Trial Conduct Prompted by the COVID-19 Pandemic Should Persist
The AACR COVID-19 and Cancer Task Force recommends keeping changes to clinical trial practices that were prompted by the pandemic.
Nanoparticle Albumin-Bound mTOR Inhibitor Gets Priority Review for Ultra-Rare Sarcoma
Nab-sirolimus is an mTOR inhibitor bound to human albumin.
- Loading...
Loading...
Next post in News
Loading... 
Loading...